Santen Pharmaceutical, a Japanese pharmaceutical company specializing in ophthalmology, and Verily, Alphabet's research organization devoted to the study of life sciences, agreed to establish a joint venture focused on applying microelectronics and scalable digital technologies to ophthalmology. Financial terms were not disclosed. "This joint venture will combine Verily's cutting-edge digital technology and our global industrial and commercial ophthalmology business platform to pursue innovation in ophthalmology. Santen has actively promoted collaboration and open innovation with various external organizations in order to enhance eye health, and corresponding quality of life, for people around the world. Digital technology is a transformational driver in health and we hope that this joint venture will be a significant step forward in paving the way for better eye care around the world," Shigeo Taniuchi, Santen President and COO.